Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501

Business Wire11-19

IPH6501 is a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 and developed for B-NHL IPH6501 boosts NK cell proliferation and cytotoxicity, showing activity ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484160962?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pQqn38s7_Tg38pELAwwAoA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/e61b89b5b7c85a0735c33778cd236a9b","is_english":true,"pubTime":"2024-11-19 14:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2484160962","market":"us","top_or_hot":-1,"title":"Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501","media":"Business Wire","content":"<div>\n<p>IPH6501 is a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 and developed for B-NHL\nIPH6501 boosts NK cell proliferation and cytotoxicity, showing activity ...</p>\n\n<a href=\"https://finance.yahoo.com/news/innate-pharma-announces-publication-science-060000985.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-19 14:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/innate-pharma-announces-publication-science-060000985.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IPH6501 is a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 and developed for B-NHL\nIPH6501 boosts NK cell proliferation and cytotoxicity, showing activity ...</p>\n\n<a href=\"https://finance.yahoo.com/news/innate-pharma-announces-publication-science-060000985.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPHA","symbol_name":"Innate Pharma SA","start_time":0,"source_url":"https://finance.yahoo.com/news/innate-pharma-announces-publication-science-060000985.html","article_id":"2484160962","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pQqn38s7_Tg38pELAwwAoA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/e61b89b5b7c85a0735c33778cd236a9b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484160962","pubTimestamp":1731996000,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"IPH6501 is a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 and developed for B-NHL. IPH6501 boosts NK cell proliferation and cytotoxicity, showing activity in vitro against a range of B-NHL cell lines, in vivo in various preclinical models and ex vivo in samples from R/R B-NHL patients. Innate Pharma SA   today announced the publication in Science Immunology of preclinical data demonstrating the potential of IPH6501, Innate’s proprietary NK cell engager including an IL-2v and targeting CD20 from the ANKET platform. IPH6501 is currently evaluated in a Phase 1/2 clinical trial in B-cell non-Hodgkin lymphoma  .","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPHA":"Innate Pharma SA","IPHYF":"Innate Pharma","BK4080":"零售业房地产投资信托","BK4231":"零售房地产信托","ADC":"艾格里房产","BK4139":"生物科技"},"translate_title":"Innate Pharma宣布在《科学免疫学》上发表文章，重点介绍创新的下一代ANKET®IPH6501","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1,"IPHYF":1,"IPHA":0.9},"content_text":"IPH6501 is a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 and developed for B-NHL\nIPH6501 boosts NK cell proliferation and cytotoxicity, showing activity in vitro against a range of B-NHL cell lines, in vivo in various preclinical models and ex vivo in samples from R/R B-NHL patients\nIn vivo studies further validated that IPH6501 augments the ability of peripheral NK cells to migrate and infiltrate tumors\nResults support clinical development of IPH6501 in R/R B-NHL\n\nMARSEILLE, France, November 19, 2024--(BUSINESS WIRE)--Regulatory News:\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\"Innate\" or the \"Company\") today announced the publication in Science Immunology of preclinical data demonstrating the potential of IPH6501, Innate’s proprietary NK cell engager including an IL-2v and targeting CD20 from the ANKET® platform. IPH6501 is currently evaluated in a Phase 1/2 clinical trial in B-cell non-Hodgkin lymphoma (B-NHL) (NCT06088654).\nThe data published shows that IPH6501, also called CD20-NKCE-IL2v in the publication, boosts NK cell proliferation and cytotoxicity, showing activity against a range of B-NHL cell lines, including those with low CD20 density. In vivo studies in nonhuman primates and tumor mouse models further validated its efficacy and revealed that IPH6501 induces peripheral NK cell migration at the tumor site.\n\"These new findings underscore the remarkable potential of IPH6501 to transform the treatment landscape for B-NHL. IPH6501 showed greater killing efficacy over a T cell engager targeting CD20 in in vitro preclinical models while presenting reduced toxicities compared with those commonly associated with T cell therapies. We are particularly encouraged by results that reveal IPH6501’s ability to drive NK cell migration directly to tumor sites, highlighting its potential as a game-changer in immuno-oncology. These findings are a testament to the promise of NK cell therapies to deliver safer and more targeted solutions for patients in need,\" commented Eric Vivier, DVM, PhD, Chief Scientific Officer of Innate Pharma.\nThe data published further support the current clinical development plan of IPH6501 in Relapsed/Refractory B-NHL.\nAbout ANKET®\nANKET® (Antibody-based NK cell Engager Therapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer. This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer.\nAbout IPH6501\nIPH6501 is the first Antibody-based NK cell Engager Therapeutic to co-engage activating receptors on NK cells (NKp46 and CD16), IL-2R (but not a subunit) through a variant of human IL-2, and a tumor antigen (CD20) via a single molecule, hence providing proliferation and activation signals targeted to NK cells and promoting their cytotoxic activity against CD20 expressing malignant cells.\nIPH6501 has shown better anti-tumor efficacy than approved benchmark antibodies in preclinical tumor models (Demaria, EHA 2023, Carrette, SITC 2024, Demaria et al, Science Immunology 2024).\nIPH6501 is currently being evaluated in a Phase 1/2 multicenter trial (NCT06088654), investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma.\nAbout Innate Pharma\nInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: monoclonal antibodies, multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC).\nInnate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, several ANKET® drug candidates to address multiple tumor types as well as IPH4502 a differentiated ADC in development in solid tumors.\nInnate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.\nHeadquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.\nLearn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.\nInformation about Innate Pharma shares\n\n\n\nISIN code Ticker code LEI\n\nFR0010331421Euronext: IPH Nasdaq: IPHA9695002Y8420ZB8HJE29\n\n\n\nDisclaimer on forward-looking information and risk factors\nThis press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including \"anticipate,\" \"believe,\" \"can,\" \"could,\" \"estimate,\" \"expect,\" \"may,\" \"might,\" \"potential,\" \"expect\" \"should,\" \"will,\" or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\"Facteurs de Risque\") section of the Universal Registration Document filed with the French Financial Markets Authority (\"AMF\"), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, www.innate-pharma.com, and public filings and reports filed with the U.S. Securities and Exchange Commission (\"SEC\"), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.\nIn light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20241118258203/en/\nContacts\nFor additional information, please contact: Investors Innate Pharma Henry WheelerTel.: +33 (0)4 84 90 32 88Henry.wheeler@innate-pharma.fr\nMedia Relations NewCap Arthur RouilléTel.: +33 (0)1 44 71 00 15innate@newcap.eu","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484160962"}